Resection of early stage non-small cell lung cancer (NSCLC) offers patients the best hope
of cure, however recurrence rates post-resection remain high suggesting the presence of …

The advent of multi-cancer early detection (MCED) tests has the potential to revolutionise
the diagnosis of cancer, improving patient outcomes through early diagnosis and increased …

Lung cancer (LC) is the most common global cancer. An individual’s risk of developing LC
is mediated by an array of factors, including family history of the disease. Considerable …

Introduction Lung cancer is the world’s leading cause of cancer death. Low-dose computed
tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National …

Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate
the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX …

Background The National Health Service England (NHS) classifies individuals as eligible for
lung cancer screening using two risk prediction models, PLCOm2012 and Liverpool Lung …

Introduction Low-dose CT (LDCT) screening reduces lung cancer specific mortality. Several
countries, including the UK, are evaluating the clinical impact and cost-effectiveness of …

Background Screening with low-dose computed tomography (LDCT) reduces lung cancer
mortality; however, the most effective strategy for optimising participation is unknown. Here we …

Tumor recurrence after surgical resection of NSCLC obstructs long-term disease-free survival
in approximately 50% of cases. Our data suggest that combining circulating tumor cell …

Background Over the last 10 years, endobronchial ultrasound-guided transbronchial needle
aspiration (EBUS-TBNA) has become established as the first-line nodal staging procedure …